Recursion Pharmaceuticals, Inc. (RXRX) Market Cap & Valuation Ratios
Recursion Pharmaceuticals, Inc. (RXRX) has a market cap of $2.0B and a price-to-sales ratio of 36.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RXRX | 2.0 | — | 26.4 | — | — | -15% | — | -136% |
| HRMY | 2.1 | 11.7 | 1.7 | 6.2 | 16.9% | +24% | 24% | 35% |
| BHVN | 2.1 | — | — | — | — | — | — | -437% |
| IMNM | 2.0 | — | — | — | -10.7% | — | — | -125% |
| VERA | 2.0 | — | — | — | — | — | — | -90% |
| ZYME | 2.0 | — | 49.1 | — | -6.0% | -70% | -419% | — |
| MRVI | 1.9 | — | 9.5 | — | -1.9% | -5% | -56% | -41% |
| SEPN | 1.9 | — | 15.3 | — | 5.6% | — | -44% | -18% |
| SRPT | 1.9 | — | 1.0 | — | 4.4% | -20% | -7% | -8% |
| XNCR | 1.9 | — | 15.2 | — | -11.1% | -29% | -206% | -34% |
| MLYS | 1.8 | — | — | — | -7.6% | — | — | -73% |
| Median of these 10 | 11.7 | 12.4 | 6.2 | -4.0% | -20% | -50% | -41% |
; EV/Sales 26.4 vs. 12.4.
Growth vs. price
each dot a company · hover or tap for valuesRecursion Pharmaceuticals, Inc. — questions
- What is Recursion Pharmaceuticals, Inc.'s market cap?
- $2.0B.
- What is Recursion Pharmaceuticals, Inc.'s price-to-sales ratio?
- 36.1.
Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.